DE69228938T2 - Methode und zusammensetzungen zur behandlung von zerebralparalyse - Google Patents

Methode und zusammensetzungen zur behandlung von zerebralparalyse

Info

Publication number
DE69228938T2
DE69228938T2 DE69228938T DE69228938T DE69228938T2 DE 69228938 T2 DE69228938 T2 DE 69228938T2 DE 69228938 T DE69228938 T DE 69228938T DE 69228938 T DE69228938 T DE 69228938T DE 69228938 T2 DE69228938 T2 DE 69228938T2
Authority
DE
Germany
Prior art keywords
compositions
treating cerebral
cerebral paralysis
paralysis
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228938T
Other languages
English (en)
Other versions
DE69228938T3 (de
DE69228938D1 (de
Inventor
Herbert Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10701881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69228938(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69228938D1 publication Critical patent/DE69228938D1/de
Publication of DE69228938T2 publication Critical patent/DE69228938T2/de
Publication of DE69228938T3 publication Critical patent/DE69228938T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69228938T 1991-09-24 1992-09-16 Verwendung von präsynaptischen Neurotoxin zur Behandlung von Zerebralparalyse Expired - Lifetime DE69228938T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919120306A GB9120306D0 (en) 1991-09-24 1991-09-24 Method and compositions for the treatment of cerebral palsy
GB9120306 1991-09-24
PCT/GB1992/001697 WO1993005800A1 (en) 1991-09-24 1992-09-16 Method and compositions for the treatment of cerebral palsy

Publications (3)

Publication Number Publication Date
DE69228938D1 DE69228938D1 (de) 1999-05-20
DE69228938T2 true DE69228938T2 (de) 1999-09-23
DE69228938T3 DE69228938T3 (de) 2008-01-03

Family

ID=10701881

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228938T Expired - Lifetime DE69228938T3 (de) 1991-09-24 1992-09-16 Verwendung von präsynaptischen Neurotoxin zur Behandlung von Zerebralparalyse

Country Status (13)

Country Link
US (7) US6395277B1 (de)
EP (1) EP0605501B2 (de)
JP (2) JP3535872B2 (de)
AT (1) ATE178799T1 (de)
AU (1) AU666334B2 (de)
CA (1) CA2119562C (de)
DE (1) DE69228938T3 (de)
DK (1) DK0605501T5 (de)
ES (1) ES2131073T5 (de)
GB (1) GB9120306D0 (de)
GR (1) GR3030418T3 (de)
NO (2) NO312747B1 (de)
WO (1) WO1993005800A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (ja) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
DE69432299T2 (de) * 1993-06-10 2003-12-11 Allergan Inc Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
EP1512411B1 (de) * 1993-06-10 2009-11-18 Allergan, Inc. Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
ES2319860T3 (es) * 1993-12-28 2009-05-14 Allergan, Inc. Uso de toxina botulinica de tipo b para la fabricacion de un medicamento para reducir el dolor asociado a un trastorno muscular.
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
AU2431995A (en) * 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
PL320214A1 (en) * 1994-10-24 1997-09-15 Ophidian Pharmaceuticals Vaccine and antitoxin for treating and preventing a disease caused by c.difficile
JP2002501033A (ja) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
EP1301213B1 (de) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Mehrkomponentensysteme zur transport von biologischen wirkstoffen
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
EP1443932B1 (de) 2001-11-15 2012-12-26 Micro Algae Corporation Pharmazeutische zusammensetzungen mit 3,4-propinoperhydropurinen und ihre verwendung zur blockierung der neuronalen übertragung
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
AU2003221050A1 (en) * 2002-03-29 2003-10-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remedy for hypermyotonia
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1594523B1 (de) * 2002-12-20 2009-03-25 Botulinum Toxin Research Associates, Inc. Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
KR20050109969A (ko) * 2003-03-06 2005-11-22 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 보툴리눔 톡신으로 부비동염 관련 만성 안면통 및 두통을치료하는 방법
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN1946431B (zh) * 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US20050206225A1 (en) * 2004-03-18 2005-09-22 Ford Global Technologies, Llc Method and apparatus for predicting the position of a trailer relative to a vehicle
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
CN1997373B (zh) * 2004-05-07 2010-12-22 菲特托克斯有限公司 藻毒素及其用途
US20080045889A1 (en) * 2004-07-21 2008-02-21 Gerondale Scott J Botoxo Needle Injector
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
US9314416B2 (en) 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0613631A8 (pt) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
JP5826450B2 (ja) * 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
EP1948230A4 (de) * 2005-11-17 2010-03-10 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulintoxinen mit reduziertem anteil nicht-toxischer proteine
PT3295955T (pt) 2005-12-01 2021-07-12 Univ Massachusetts Lowell Nanoemulsões botulínicas
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
JP5292304B2 (ja) 2006-12-01 2013-09-18 アンテリオス， インコーポレイテッド ペプチドナノ粒子およびその使用
BRPI0719756A2 (pt) 2006-12-01 2014-01-21 Anterios Inc Nanopartículas de entidades anfifílicas
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
NZ598039A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
EP2529686B1 (de) 2008-05-09 2015-10-14 Holaira, Inc. System zur Behandlung eines Bronchialbaumes
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
EP2330910B1 (de) * 2008-09-11 2017-08-16 Israeli Biotechnology Research Ltd. Kosmetische verwendung von märzenbecherextrakten
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
JP4697289B2 (ja) 2008-11-05 2011-06-08 ソニー株式会社 撮像装置、撮像装置の表示制御方法
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CA2780608C (en) 2009-11-11 2019-02-26 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
EP2729163A1 (de) 2011-07-08 2014-05-14 Allergan, Inc. Verfahren zur behandlung von autonomen nervensystemerkrankungen
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
KR20140054055A (ko) 2011-07-14 2014-05-08 알러간, 인코포레이티드 성행위와 관련된 실금의 치료방법
MX2014000612A (es) 2011-07-20 2014-02-27 Allergan Inc Toxinas botulinicas para usar en un metodo para el tratamiento de depositos adiposos.
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX358006B (es) 2012-09-25 2018-08-02 Haldor Topsoe As Catalizador de reformado de vapor y metodo para la fabricacion del mismo.
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
MX2017016910A (es) 2015-07-08 2018-08-15 Gilrose Pharmaceuticals Llc Tratamiento del deterioro del modo de andar y de las extremidades y del trastorno de procesamiento de la corteza pre-frontal.
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
EP3801581A4 (de) * 2018-05-24 2022-04-06 Children's Hospital Medical Center Zusammensetzungen und verfahren zur behandlung von muskelkontrakturen
WO2022075785A1 (ko) * 2020-10-07 2022-04-14 주식회사 프로톡스 보툴리눔 독소의 진공 건조 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4234566A (en) * 1979-06-29 1980-11-18 Packman Elias W Antihistamine and methods for use thereof
US4720494A (en) * 1984-11-05 1988-01-19 The Gillette Company Anticholinergic eucatropine esters and antiperspirant use thereof
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
EP0262396A3 (de) 1986-09-20 1989-08-23 Heinz Dipl.-Ing. Hölter Verfahren zum Herstellen von Calciumsulfatdihydrat bei der Rauchgasentschwefelung
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4935969A (en) * 1987-12-02 1990-06-26 Farnsworth Orin J Method and device for the controlled disposal of human waste
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5056291A (en) * 1989-10-19 1991-10-15 Skilland Engineering, Ltd. Modular system for space frame structures
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
JP3510886B2 (ja) 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
JPH06192296A (ja) 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
EP0679090A1 (de) 1993-01-15 1995-11-02 Interactive Biologics Associates Verfahren zur behandlung von gesichtsmuskel schmez syndrom
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
DE69432299T2 (de) 1993-06-10 2003-12-11 Allergan Inc Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
EP1512411B1 (de) * 1993-06-10 2009-11-18 Allergan, Inc. Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
ES2319860T3 (es) 1993-12-28 2009-05-14 Allergan, Inc. Uso de toxina botulinica de tipo b para la fabricacion de un medicamento para reducir el dolor asociado a un trastorno muscular.
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU2431995A (en) 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
TWI243265B (en) 2002-02-27 2005-11-11 Chi Mei Optoelectronics Corp Method for forming a reflection-type light diffuser

Also Published As

Publication number Publication date
US6395277B1 (en) 2002-05-28
US20020142010A1 (en) 2002-10-03
ES2131073T5 (es) 2007-06-16
NO941065D0 (no) 1994-03-23
AU2566492A (en) 1993-04-27
CA2119562A1 (en) 1993-04-01
AU666334B2 (en) 1996-02-08
US20010046962A1 (en) 2001-11-29
US6448231B2 (en) 2002-09-10
EP0605501A1 (de) 1994-07-13
DE69228938T3 (de) 2008-01-03
CA2119562C (en) 2005-02-15
DK0605501T3 (da) 1999-10-25
JPH06510779A (ja) 1994-12-01
EP0605501B1 (de) 1999-04-14
NO312747B1 (no) 2002-07-01
US20050112146A1 (en) 2005-05-26
NO20013727L (no) 1994-03-23
DE69228938D1 (de) 1999-05-20
DK0605501T5 (da) 2007-02-26
US20050142150A1 (en) 2005-06-30
NO941065L (no) 1994-03-23
US20070224221A1 (en) 2007-09-27
NO324159B1 (no) 2007-09-03
JP2002097154A (ja) 2002-04-02
JP3535872B2 (ja) 2004-06-07
ES2131073T3 (es) 1999-07-16
NO20013727D0 (no) 2001-07-30
US7378389B2 (en) 2008-05-27
WO1993005800A1 (en) 1993-04-01
EP0605501B2 (de) 2006-11-29
GB9120306D0 (en) 1991-11-06
US20080206224A1 (en) 2008-08-28
GR3030418T3 (en) 1999-09-30
ATE178799T1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
DE69228938T2 (de) Methode und zusammensetzungen zur behandlung von zerebralparalyse
ATE477816T1 (de) Botulinum toxin zur behandlung von akuten verletzungen der skelettmuskeln
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
ATE281840T1 (de) Behandlung von diarrhoe
DE69403969T2 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE68919673D1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
UA41153A (uk) Спосіб немедикаментозного лікування симпато-адреналових пароксизмів

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de
R071 Expiry of right

Ref document number: 605501

Country of ref document: EP